Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2025 06:00 ET | Source: Research and Markets

Ovarian Cancer Market Research 2024: Creation of Novel Biomarkers and Genetic Testing Gaining Pace - Global $31.3 Billion Market Forecasts to 2034

Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
December 23, 2024 11:35 ET | Source: Research and Markets

Gynecological Cancer Drugs Research Report 2024: Personalized Medicine Revolutionizes Gynecological Cancer Care with Targeted Therapies - Explore Potential $24 Billion Opportunities by 2030

Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Gynecological Cancer Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
June 10, 2024 10:11 ET | Source: Research and Markets

Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics)

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
April 09, 2024 07:02 ET | Source: Research and Markets

Ovarian Cancer Opportunity Assessment Report 2024: A Blockbuster Market that is Expected to Grow from $3.3 Billion in 2022 to $4.1 Billion in 2032 with ImmunoGen, AstraZeneca, Merck, & GSK Dominating

Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.Ovarian Cancer is one of the most...
August 25, 2022 05:53 ET | Source: Research and Markets

Global Gynecological Cancer Drugs Market Report 2022: Advancement of Cancer Drug Research and the Advent of Personalized Medicine Presents Opportunities

Dublin, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The "Gynecological Cancer Drugs Market By Therapeutic Modality, By Indication: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been...
August 15, 2022 13:50 ET | Source: Straits Research

Next-Generation Gynecological Cancer Diagnostics Market Size is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 10.68%: Straits Research

New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Uterine, ovarian, and cervical cervix cancers are the most common in women. Cervical cancer ranks fourth among women's...
April 28, 2022 04:43 ET | Source: Research and Markets

World Next-Generation Gynecological Cancer Diagnostics Market Research Report 2022 Featuring Laboratory Corp of America, F. Hoffmann-La Roche, Illumina, Agilent Technologies, BGI, and PerkinElmer

Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and...
November 11, 2021 06:53 ET | Source: Research and Markets

$31+ Billion Worldwide Gynecology Drugs Industry to 2030 - Identify Growth Segments for Investment

Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Gynecology Drugs Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report...
November 20, 2017 07:00 ET | Source: TESARO, Inc.

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer

ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...